Celltrion Healthcare Co., Ltd.
091990
Rangering i aksjer
#2142
Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on... Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.
Aksjekurs
$57.75
Sist synkronisert: 2024-01-11
Markedsverdi
$9.42B
Endring (1 dag)
-0.25%
Endring (1 år)
0.00%
Land
KR
Handel Celltrion Healthcare Co., Ltd. (091990)
Kategori
Healthcare
Inntekter for Celltrion Healthcare Co., Ltd. (091990)
Inntekter i Oct 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Celltrion Healthcare Co., Ltd. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Celltrion Healthcare Co., Ltd. fra 2014 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2022 | $1.56B | 2.97% |
| 2021 | $1.52B | 1.24% |
| 2020 | $1.50B | 57.26% |
| 2019 | $953.35M | 48.78% |
| 2018 | $640.76M | -25.89% |
| 2017 | $864.65M | 37.82% |
| 2016 | $627.36M | 96.07% |
| 2015 | $319.97M | 110.23% |
| 2014 | $152.20M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| $10.11B | - |
BE
|
